Advertisement
Mayo Clinic Proceedings Home

Arthrocentesis and Joint Injection in Patients Receiving Direct Oral Anticoagulants

      Abstract

      Anticoagulation is common in patients undergoing arthrocentesis and joint injections. Previous studies have established the safety of continuing anticoagulation with warfarin before joint aspirations/injections with only a small increased risk of bleeding, but no data are available regarding the use of direct oral anticoagulants (DOACs) and joint aspirations/injections. The objective of this study was to determine the rate of bleeding complications associated with arthrocentesis and joint injection in patients receiving DOACs. We performed a retrospective review of adult patients at Mayo Clinic in Rochester, Minnesota, who were being treated with DOACs and underwent outpatient joint aspiration and/or injection between October 1, 2010, and October 31, 2016. In 1050 consecutive procedures, there were no bleeding complications. Arthrocentesis and joint injections in patients receiving DOAC therapy are safe procedures, and there is no need to withhold anticoagulation treatment before the procedure.

      Abbreviations and Acronyms:

      DOAC (direct oral anticoagulant), FDA (Food and Drug Administration), INR (international normalized ratio), VTE (venous thromboembolism)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ahmed I.
        • Gertner E.
        Safety of arthrocentesis and joint injection in patients receiving anticoagulation at therapeutic levels.
        Am J Med. 2012; 125: 265-269
        • Agnelli G.
        • Buller H.R.
        • Cohen A.
        • et al.
        • AMPLIFY Investigators
        Oral apixaban for the treatment of acute venous thromboembolism.
        N Engl J Med. 2013; 369: 799-808
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        • RE-LY Steering Committee and Investigators
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361 ([published correction appears in N Engl J Med. 2010;363(19):1877]): 1139-1151
        • Hokusai VTE Investigators
        Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
        N Engl J Med. 2013; 369 ([published correction appears in N Engl J Med. 2014;370(4):390]): 1406-1415
        • EINSTEIN-PE Investigators
        Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
        N Engl J Med. 2012; 366: 1287-1297
        • Robertson L.
        • Kesteven P.
        • McCaslin J.E.
        Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
        Cochrane Database Syst Rev. 2015; : CD010956
        • Robertson L.
        • Kesteven P.
        • McCaslin J.E.
        Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
        Cochrane Database Syst Rev. 2015; : CD010957
        • Bashir M.A.
        • Ray R.
        • Sarda P.
        • Li S.
        • Corbett S.
        Determination of a safe INR for joint injections in patients taking warfarin.
        Ann R Coll Surg Engl. 2015; 97: 589-591
        • Conway R.
        • O'Shea F.D.
        • Cunnane G.
        • Doran M.F.
        Safety of joint and soft tissue injections in patients on warfarin anticoagulation.
        Clin Rheumatol. 2013; 32: 1811-1814
        • Guillen Astete C.
        • Boteanu A.
        • Medina Quiñones C.
        • et al.
        Is it safe to perform joint infiltrations or aspirations in patients anticoagulated with acenocoumarol?.
        Reumatol Clin. 2015; 11: 9-11
        • Thumboo J.
        • O'Duffy J.D.
        A prospective study of the safety of joint and soft tissue aspirations and injections in patients taking warfarin sodium.
        Arthritis Rheum. 1998; 41: 736-739
        • Salvati G.
        • Punzi L.
        • Pianon M.
        • et al.
        Frequency of the bleeding risk in patients receiving warfarin submitted to arthrocentesis of the knee.
        Reumatismo. 2003; 55 ([in Italian]): 159-163
        • Baron T.H.
        • Kamath P.S.
        • McBane R.D.
        Management of antithrombotic therapy in patients undergoing invasive procedures.
        N Engl J Med. 2013; 368: 2113-2124
      1. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015.

        • Noseworthy P.A.
        • Yao X.
        • Abraham N.S.
        • Sangaralingham L.R.
        • McBane R.D.
        • Shah N.D.
        Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation.
        Chest. 2016; 150: 1302-1312